

2/5/1 DIALOG(R)File 351:Derwent WPI (c) 2002 Thomson Derwent. All rts. reserv.

010905176

WPI Acc No: 1996-402127/199640

XRAM Acc No: C96-126391

Compsn. for stimulating or enhancing growth of hair or nail  
tissue - comprises non-steroidal anabolic hormone(s), aminoacid(s),  
vitamin(s), inorganic ions and glucose

Patent Assignee: LIFE MEDICAL SCI INC (LIFE-N); HOWMET CORP (HOWM )

Inventor: LINDENBAUM E

Number of Countries: 070 Number of Patents: 004

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 9625943	A1	19960829	WO 96US2341	A	19960221	199640 B
AU 9649904	A	19960911	AU 9649904	A	19960221	199651
JP 9010915	A	19970114	JP 9659965	A	19960222	199712
EP 812210	A1	19971217	EP 96906564	A	19960221	199804
			WO 96US2341	A	19960221	

Priority Applications (No Type Date): US 95537515 A 19951002; US 95394005 A 19950223

Cited Patents: 3.Jnl.Ref; US 4205126

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
WO 9625943	A1	E	59 A61K-038/28	

Designated States (National): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE  
DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN  
MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN

Designated States (Regional): AT BE CH DE DK EA ES FR GB GR IE IT KE LS  
LU MC MW NL OA PT SD SE SZ UG

AU 9649904	A	A61K-038/28	Based on patent WO 9625943
------------	---	-------------	----------------------------

JP 9010915	A	9 B22D-018/06	
------------	---	---------------	--

EP 812210	A1	E	A61K-038/28	Based on patent WO 9625943
-----------	----	---	-------------	----------------------------

Designated States (Regional): AL AT BE CH DE DK ES FR GB GR IE IT LI LT  
LU LV MC NL PT SE SI

Abstract (Basic): WO 9625943 A

Compsn., comprising at least one non-steroidal anabolic hormone selected from insulin, triiodothyronine (T3) and thyroxine (T4), in combination with a minimum essential medium (MEM), contg. essential amino acids, a vitamin mixt. of folate, niacinamide, pantothenate, pyridoxine, riboflavin, and thiamine, an inorganic ion mixt. of calcium, sodium, potassium, chloride and magnesium, and glucose; for use in: (a) stimulating or enhancing the growth of hair or ungual (nail) tissue in intact skin; (b) revitalising skin; and (c) restoring natural colour to hair in intact skin, in which the hair colour has diminished; is new.

USE - The compsn. promotes vascularisation and angiogenesis in the dermis, stimulating dormant, dying, or weak hair follicles to produce hair and promote its growth. It also promotes melanogenesis in the follicles, restoring the natural colour of grey, greying, and damaged hair. The increased vascularisation and blood flow also has a revitalising effect on the skin, to become smoother, softer, more moist, oily, and waxy, more pleasing to the vision and touch cosmetically. In addn. to human use, the compsn. can also be of value to increase hair prodn. by domesticated animals, a partic. example being sheep. Opt. addns. to the compsn. are penetration enhancer(s), and gelling agent(s), if a gel form is desired. Addn. of growth hormone (GH), partic. human GH (hGH) for human use, is pref.

ADVANTAGE - The compsn. shows little, if any, toxicity, unlike Minoxidil, which can have hepatotoxic, tachycardiac, and contact dermatitis side effects.

Dwg.0/2

Title Terms: COMPOSITION; STIMULATING; ENHANCE; GROWTH; HAIR; NAIL; TISSUE; COMPRISE; NON; STEROIDAL; ANABOLIC; HORMONE; AMINOACID; VITAMIN; INORGANIC; ION; GLUCOSE

Derwent Class: B05; D21; E19; P53; Q51

International Patent Class (Main): A61K-038/28; B22D-018/06

International Patent Class (Additional): A61K-031/195; A61K-038/00;

B22C-009/04; B22D-027/04; B22D-027/13; F01D-005/18

File Segment: CPI; EngPI

Derwent WPI (Dialog® File 351): (c) 2002 Thomson Derwent. All rights reserved.

---

© 2002 The Dialog Corporation

1/5/1 DIALOG(R)File 351:Derwent WPI (c) 2002 Thomson Derwent. All rts. reserv.

011931212      \*\*Image available\*\*

WPI Acc No: 1998-348122/199830

XRAM Acc No: C98-107565

**New biaromatic compounds are useful in treatment of cell proliferation and differentiation disorders - as well as e.g. ophthalmological disorders, cardiovascular disorders, non-insulin-dependent diabetes and Uv-induced cutaneous disorders**

Patent Assignee: CIRD CENT INT RECH DERMATOLOGIQUES (CIRD ); GALDERMA RES & DEV (CIRD )

Inventor: BERNARDON J; DIAZ P; BERNARDON J M

Number of Countries: 078 Number of Patents: 015

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 9822423	A1	19980528	WO 97FR2063	A	19971117	199830 B
FR 2755965	A1	19980522	FR 9614098	A	19961119	199830
AU 9852254	A	19980610	AU 9852254	A	19971117	199843
BR 9707153	A	19990406	BR 977153	A	19971117	199920
			WO 97FR2063	A	19971117	
JP 11503472	W	19990326	WO 97FR2063	A	19971117	199923
			JP 98523275	A	19971117	
EP 915823	A1	19990519	EP 97947075	A	19971117	199924
			WO 97FR2063	A	19971117	
NZ 330844	A	19991028	NZ 330844	A	19971117	199953
			WO 97FR2063	A	19971117	
MX 9805705	A1	19981001	MX 985705	A	19980715	200019
AU 719468	B	20000511	AU 9852254	A	19971117	200031
EP 915823	B1	20010418	EP 97947075	A	19971117	200123
			WO 97FR2063	A	19971117	
DE 69704619	E	20010523	DE 604619	A	19971117	200137
			EP 97947075	A	19971117	
			WO 97FR2063	A	19971117	
US 6258775	B1	20010710	US 97101622	A	19971117	200141
			WO 97FR2063	A	19971117	
JP 2001233821	A	20010828	JP 98523275	A	19971117	200157
			JP 2000399456	A	19971117	
ES 2158597	T3	20010901	EP 97947075	A	19971117	200161
JP 3232484	B2	20011126	WO 97FR2063	A	19971117	200201
			JP 98523275	A	19971117	

Priority Applications (No Type Date): FR 9614098 A 19961119

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 9822423 A1 F 70 C07C-059/84

Designated States (National): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU

Designated States (Regional): AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW

FR 2755965 A1 C07C-059/72

AU 9852254 A Based on patent WO 9822423

BR 9707153 A Based on patent WO 9822423

JP 11503472 W 86 C07C-059/84 Based on patent WO 9822423

EP 915823 A1 F Based on patent WO 9822423

Designated States (Regional): AT BE CH DE DK ES FI FR GB GR IE IT LI LU

MC NL PT SE			
NZ 330844	A		Based on patent WO 9822423
MX 9805705	A1	C07C-059/84	
AU 719468	B	C07C-059/84	Previous Publ. patent AU 9852254 Based on patent WO 9822423
EP 915823	B1 F	C07C-059/84	Based on patent WO 9822423
Designated States (Regional): AT BE CH DE DK ES FI FR GB GR IE IT LI LU			
MC NL PT SE			
DE 69704619	E	C07C-059/84	Based on patent EP 915823 Based on patent WO 9822423
US 6258775	B1	A61K-038/00	Based on patent WO 9822423
JP 2001233821	A	42 C07C-059/86	Div ex application JP 98523275
ES 2158597	T3	C07C-059/84	Based on patent EP 915823
JP 3232484	B2	28 C07C-059/84	Previous Publ. patent JP 11503472 Based on patent WO 9822423

## Abstract (Basic): WO 9822423 A

Biaromatic compounds of formula (I), their optical and geometric isomers and their salts are new. R1 = Me, CH2OR5, OR5 or COR6; Y = (R7)C=C(R7') or C triple bond C; Ar = Ph (substituted by R8) or furandiyl, thiophendiyl or pyridindiyl; Y may be ortho or meta to X; X = O, S, SO, SO2, N(R9), C(O), C=CH2, C=C(Me)2, CH2, CH(OR5), CH(R12), CH(NHOH), C=N-OR5, 1,3-dioxolan-2-diyl, 1,3-dioxan-2-diyl, 1,3-dithian-2-diyl, 1,3-dithiolan-2-diyl, oxiran-1-diyl or cyclopropan-1-diyl; R2, R3 = H, alkyl, OR5, SR5, polyether or alkyl containing at least 3 C atoms, the carbon attached to the phenyl group being substituted by at least 2 C atoms; or R2+R3 = 5- or 6-membered aromatic ring (optionally substituted by methyl and optionally interrupted by O or S); provided that when R2+R3 do not form a ring, then at least one of R2 and R3 is an alkyl containing at least 3 C atoms, the carbon attached to the phenyl group being substituted by at least 2 C atoms; R4, R8 = H, halogen, alkyl, OR5 or polyether; R5 = H, lower alkyl or COR10; R6 = H, lower alkyl, N(R')(R'') or OR11; R7, R7', R9 = H or lower alkyl; n = 0 or 1; R10 = lower alkyl; R11 = H, alkyl, alkenyl, mono- or poly-hydroxy alkyl, aryl or aralkyl (all optionally substituted) or residue of a sugar, amino acid or peptide; R12 = lower alkyl; R', R'' = H, lower alkyl, mono- or poly-hydroxy alkyl, optionally substituted aryl or residue of a sugar, amino acid or peptide; or R'+R'' = heterocycle.

USE - (I) are useful in the treatment of keratinisation disorders, inflammatory conditions which are not related to keratinisation disorders, malignant or benign dermal or epidermal proliferation, bullous dermatosis, collagen diseases, ophthalmological disorders, cardiovascular disorders, non-insulin-dependent diabetes, and UV-induced cutaneous disorders. (I) are also used to combat or repair damage caused by skin ageing, to reduce pigmentation and actinic keratosis, to prevent or repair vergetures, to promote cicatrization, to combat sebaceous function disorders such as hyperseborrhoea of acne or simple seborrhoea. They are useful in the prevention or treatment of e.g. cutaneous atrophy, cicatrization disorders, alopecia and cancerous or precancerous states such as promyelocytic leukaemia. They are used in pharmaceutical compositions in an amount of 0.001-5 wt.% and in cosmetic compositions for bodily and capillary hygiene in an amount of 0.001-3 wt.% (all claimed). Administration is enteral, parenteral, topical or ocular and in a daily dosage of 0.01-100 mg/kg, 1-3 times.

Dwg.0/2

Title Terms: NEW; BI; AROMATIC; COMPOUND; USEFUL; TREAT; CELL; PROLIFERATION; DIFFERENTIAL; DISORDER; WELL; OPHTHALMIC; DISORDER; CARDIOVASCULAR; DISORDER; NON; INSULIN; DEPEND; DIABETES; ULTRAVIOLET; INDUCE; CUTANEOUS; DISORDER

Derwent Class: B03; B05; C02; C03; D21; E13; E14

International Patent Class (Main): A61K-038/00; C07C-059/72; C07C-059/84;  
C07C-059/86

International Patent Class (Additional): A61K-007/00; A61K-007/06;  
A61K-007/42; A61K-007/48; A61K-031/165; A61K-031/19; A61K-031/192;  
A61K-031/195; A61K-031/215; A61K-031/385; A61K-031/39; A61K-031/44;  
A61K-031/5375; A61P-003/10; A61P-009/10; A61P-009/12; A61P-017/06;  
A61P-017/08; A61P-017/10; A61P-017/14; A61P-017/16; A61P-019/02;  
A61P-027/02; A61P-031/22; A61P-035/00; A61P-035/02; C07C-033/38;  
C07C-047/238; C07C-057/26; C07C-057/42; C07C-057/48; C07C-057/50;  
C07C-069/618; C07C-233/11; C07C-239/18; C07C-251/48; C07C-323/62;  
C07D-213/24; C07D-213/60; C07D-295/18; C07D-295/185; C07D-339/08

File Segment: CPI

Derwent WPI (Dialog® File 351): (c) 2002 Thomson Derwent. All rights reserved.

---

© 2002 The Dialog Corporation

4/5/1 DIALOG(R)File 351:Derwent WPI (c) 2002 Thomson Derwent. All rts. reserv.

009748278 \*\*Image available\*\*

WPI Acc No: 1994-028129/199404

Related WPI Acc No: 1995-138962; 1996-496914; 1997-401911

XRAM Acc No: C94-012900

**New phenoxy and phenyl-thio-phenyl oxamic acid dervis. -  
reduces lipid levels and can be used to treat hyperlipidaemia, esp.  
hypercholesterolaemia, atherosclerosis and coronary heart disease**

Patent Assignee: CIBA GEIGY AG (CIBA ); CIBA GEIGY CORP (CIBA ); NOVARTIS AG (NOVS )

Inventor: MAIN A J; WALKER G N; YOKOYAMA N; WALKER G

Number of Countries: 029 Number of Patents: 020

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
EP 580550	A1	19940126	EP 93810495	A	19930712	199404 B
HU 64512	T	19940128	HU 932095	A	19930720	199409
AU 9342081	A	19940127	AU 9342081	A	19930720	199410
NO 9302614	A	19940124	NO 932614	A	19930720	199411
CA 2100817	A	19940122	CA 2100817	A	19930719	199414
FI 9303260	A	19940122	FI 933260	A	19930719	199414
JP 6172275	A	19940621	JP 93179177	A	19930720	199429
ZA 9305196	A	19940831	ZA 935196	A	19930719	199435
NZ 248181	A	19951127	NZ 248181	A	19930719	199602
AU 667924	B	19960418	AU 9342081	A	19930720	199623
EP 580550	B1	19971022	EP 93810495	A	19930712	199747
DE 69314718	E	19971127	DE 614718	A	19930712	199802
			EP 93810495	A	19930712	
ES 2108855	T3	19980101	EP 93810495	A	19930712	199809
HU 214875	B	19980728	HU 932095	A	19930720	199842
NO 304111	B1	19981026	NO 932614	A	19930720	199849
IL 106360	A	19981126	IL 106360	A	19930715	199912
TW 350771	A	19990121	TW 93107124	A	19930901	199926
BR 1100830	A3	19990810	BR 971100830	A	19970512	200013
MX 191139	B	19990203	MX 934375	A	19930720	200055
KR 294381	B	20010917	KR 9313760	A	19930721	200231

Priority Applications (No Type Date): US 92918544 A 19920721

Cited Patents: 1.Jnl.Ref; EP 138757; US 4061791; US 4154961

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
EP 580550	A1	E	28	C07C-233/56	
Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE					
HU 64512	T			C07C-235/72	
AU 9342081	A			C07C-233/56	
NO 9302614	A			C07C-233/56	
CA 2100817	A			C07C-235/74	
FI 9303260	A			C07C-000/00	
JP 6172275	A		25	C07C-229/18	
ZA 9305196	A		57	C07D-000/00	
NZ 248181	A			C07C-233/56	
AU 667924	B			C07C-233/56	Previous Publ. patent AU 9342081
EP 580550	B1	E	32	C07C-233/56	
Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE					
DE 69314718	E			C07C-233/56	Based on patent EP 580550

ES 2108855	T3	C07C-233/56	Based on patent EP 580550
HU 214875	B	C07C-233/24	Previous Publ. patent HU 64512
NO 304111	B1	C07C-233/56	Previous Publ. patent NO 9302614
IL 106360	A	C07C-233/56	
TW 350771	A	A61K-031/215	
BR 1100830	A3	C07C-069/00	
MX 191139	B	C07C-233/056	
KR 294381	B	C07C-323/37	

Abstract (Basic): EP 580550 A

Oxanic acid derivs. of formula (I) and their salts are new. R = H, OH (opt. esterified or etherified); R1, R2 and R4 = H, halogen, CF3 or lower alkyl; R3 = halogen, F3, lower alkyl, aryl, aryl lower alkyl, cycloalkyl or cycloalkyl lower alkyl; or Cr8R9R10; R5 + R6 = Oxo; R7 = H or lower alkyl; R8 = H, lower alkyl, aryl, cycloalkyl, aryl lower alkyl or cycloalkyl lower alkyl; R9 = OH or acyloxy; R10, R7 = H or lower alkyl; or R9+R10 = oxo; X = NR7; W = O or S; Z = carboxyl (opt. derivatised as an ester or amide).

USE - (I) are potent lipid lowering agents and can be used in the treatment of hyper lipidaemia, esp. hypercholesterolaemia and related conditions. (I) are selective hypolipidaemic agents which enhance the clearance of cholesterol (esp. in the form of low density lipo proteins, LDL) from the circulation. They, inter alia, increase hepatic LDL receptor function. Thus they can be used in the prophylaxis and therapy of occlusive cardiovascular conditions in which hyperlipidaemia and hyperlipoproteinaemia are implicated e.g. atherosclerosis and coronary heart disease (myocardial infarction).

Dwg.0/0

Title Terms: NEW; PHENOXY; PHENYL; THIO; PHENYL; OXAMIC; ACID; REDUCE; LIPID; LEVEL; CAN; TREAT; HYPERLIPAEMIA; HYPERCHOLESTEROLAEMIC; ATHEROSCLEROSIS; CORONARY; HEART; DISEASE

Derwent Class: B05

International Patent Class (Main): A61K-031/215; C07C-000/00; C07C-069/00; C07C-229/18; C07C-233/056; C07C-233/24; C07C-233/56; C07C-235/72; C07C-235/74; C07C-323/37; C07D-000/00

International Patent Class (Additional): A61K-031/16; A61K-031/165; A61K-031/19; A61K-031/195; A61K-031/22; A61K-031/225; A61K-031/24; A61K-031/33; A61K-031/335; C07C-041/00; C07C-233/02; C07C-233/88; C07C-323/40; C07C-323/63; C07D-207/337; C07D-213/56; C07D-309/00; C07D-309/10; C07D-309/12; C07D-333/24; C07J-041/00

File Segment: CPI

Derwent WPI (Dialog® File 351): (c) 2002 Thomson Derwent. All rights reserved.

© 2002 The Dialog Corporation

2/5/1 DIALOG(R)File 351:Derwent WPI (c) 2002 Thomson Derwent. All rts. reserv.

004119924

WPI Acc No: 1984-265465/198443

XRAM Acc No: C84-112269

**Scalp hair growth promoting compsn. - comprising  
antiandrogen and thyroid hormone esp. with oestrogen**

Patent Assignee: MORTIMER C H (MORT-I)

Inventor: MORTIMER C H

Number of Countries: 019 Number of Patents: 013

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
GB 2138286	A	19841024	GB 8310543	A	19830419	198443 B
EP 123528	A	19841031	EP 84302686	A	19840419	198444
WO 8404038	A	19841025	WO 84GB135	A	19840419	198444
AU 8428284	A	19841107				198505
PT 78456	A	19841220				198507
NO 8405096	A	19850304				198516
ZA 8402986	A	19850419	ZA 842986	A	19840419	198531
JP 60501057	W	19850711	JP 84501698	A	19840419	198534
DK 8406072	A	19841218				198547
GB 2138286	B	19861008				198641
EP 123528	B	19870909				198736
CA 1226524	A	19870908				198740
DE 3465879	G	19871015				198742

Priority Applications (No Type Date): GB 8310543 A 19830419

Cited Patents: EP 33164; FR 2343474; FR 6434; GB 859546; GB 874368; PM 6434

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
-----------	------	-----	----	----------	--------------

GB 2138286	A		2		
------------	---	--	---	--	--

EP 123528	A	E			
-----------	---	---	--	--	--

Designated States (National): AU DK JP NO US

WO 8404038	A	E			
------------	---	---	--	--	--

Designated States (Regional): AT BE CH DE FR GB IT LI LU NL SE

EP 123528	B	E			
-----------	---	---	--	--	--

Designated States (Regional): AT BE CH DE FR GB IT LI LU NL SE

Abstract (Basic): GB 2138286 A

Compsn. comprises an antiandrogen (I) and a thyroid hormone (II).

USE - The compsns. prevent or arrest scalp hair loss and/or promote growth. They can be used by male and female patients, esp. for topical appln. twice daily. (I) is esp. medroxyprogesterone or cyproterone acetate. (I) may be mixed with an oestrogen such as oestradiol or its benzoate. Other antiandrogens having a progesterone-like activity may be used, e.g. allyloestrenol, gestronol, norgestrel, progesterone etc.

(II) is triiodothyronine or thyroxine. The compsn. is suitably a cream, gel, ointment, paste etc., e.g. contg. 0.001-5 wt.% (I), esp. 0.01-2.5%, and (II) to provide 2-200 micrograms per typical dose to the hair and scalp.

0/0

EP 123528 A

A pharmaceutical composition for promoting scalp hair growth comprising in combination an oestrogen in a concentration above 0.01% by weight to the maximum solubility of same in its solvent, a non-oestrogenic anti-androgen in a concentration above 0.01% by weight to the maximum solubility of same in its solvent and an amount of thyroid hormone selected from 3,3-5, triiodo-L-thyronine and the pharmaceutically acceptable derivatives or precursors thereof,



sufficient to provide a concentration of at least 0.66 micro g/ml to the maximum solubility of same in its solvent. (17pp)

Title Terms: SCALP; HAIR; GROWTH; PROMOTE; COMPOSITION; COMPRISE;  
ANTIANDROGENIC; THYROID; HORMONE; OESTROGEN

Derwent Class: B01; B05; D21

International Patent Class (Additional): A61K-007/06; A61K-031/56;  
A61K-037/02; A61K-045/06

File Segment: CPI

Derwent WPI (Dialog® File 351): (c) 2002 Thomson Derwent. All rights reserved.

---

© 2002 The Dialog Corporation

---

3/5/1 DIALOG(R)File 351:Derwent WPI (c) 2002 Thomson Derwent. All rts. reserv.

000502299

WPI Acc No: 1966-02417F/196800

**Skin treatment composition**

Patent Assignee: HELLBAUM AA (HELB )

Number of Countries: 002 Number of Patents: 002

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
GB 859546	A					196800 B
US 3198702	A					196801

Abstract (Basic): GB 859546 A

Skin treatment composition for topical therapeutic use, comprising 0.001-1 mg/g of the composition of e.g., 3,5 - diiodo - 4(41 - hydroxy - 31 - iodo - phenoxy) phenyl acetic acid, where R1 = halogen, R2 = H or halogen, R3 and R4 = hydrogen, halogen, C1-3 alkyl, R4 = H, C1-3 alkyl or acyl, R6 = H or lower alkyl, A = alkylene, substituted alkylene, etc., in a powder or cream base.

Title Terms: SKIN; TREAT; COMPOSITION

Derwent Class: B00

File Segment: CPI

Derwent WPI (Dialog® File 351): (c) 2002 Thomson Derwent. All rights reserved.

---

© 2002 The Dialog Corporation

---

3/5/1 DIALOG(R)File 351:Derwent WPI (c) 2002 Thomson Derwent. All rts. reserv.

000502299

WPI Acc No: 1966-02417F/196800

**Skin treatment composition**

Patent Assignee: HELLBAUM AA (HELB )

Number of Countries: 002 Number of Patents: 002

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
GB 859546	A					196800 B
US 3198702	A					196801

Abstract (Basic): GB 859546 A

Skin treatment composition for topical therapeutic use, comprising 0.001-1 mg/g of the composition of e.g., 3,5 - diiodo - 4(41 - hydroxy - 31 - iodo - phenoxy) phenyl acetic acid, where R1 = halogen, R2 = H or halogen, R3 and R4 = hydrogen, halogen, C1-3 alkyl, R4 = H, C1-3 alkyl or acyl, R6 = H or lower alkyl, A = alkylene, substituted alkylene, etc., in a powder or cream base.

Title Terms: SKIN; TREAT; COMPOSITION

Derwent Class: B00

File Segment: CPI

Derwent WPI (Dialog® File 351): (c) 2002 Thomson Derwent. All rights reserved.

---

© 2002 The Dialog Corporation